Perigon Wealth Management LLC Purchases 325 Shares of Cencora, Inc. (NYSE:COR)

Perigon Wealth Management LLC boosted its position in shares of Cencora, Inc. (NYSE:COR) by 15.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 2,427 shares of the company’s stock after acquiring an additional 325 shares during the period. Perigon Wealth Management LLC’s holdings in Cencora were worth $585,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Concord Wealth Partners bought a new position in shares of Cencora during the 3rd quarter valued at approximately $30,000. Householder Group Estate & Retirement Specialist LLC lifted its position in Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after purchasing an additional 69 shares during the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of Cencora in the 3rd quarter worth $41,000. Modus Advisors LLC bought a new stake in shares of Cencora in the 4th quarter worth about $54,000. Finally, Carolina Wealth Advisors LLC raised its position in shares of Cencora by 366.7% during the 3rd quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $60,000 after buying an additional 209 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on COR shares. Evercore ISI boosted their price objective on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Leerink Partners decreased their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Wells Fargo & Company lifted their price objective on shares of Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday. JPMorgan Chase & Co. increased their target price on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Finally, UBS Group lifted their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $278.40.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the transaction, the chairman now directly owns 306,752 shares in the company, valued at approximately $74,283,064.32. This trade represents a 6.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,187 shares of company stock worth $17,790,912 in the last ninety days. 10.80% of the stock is owned by company insiders.

Cencora Price Performance

Cencora stock opened at $254.11 on Friday. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The stock has a market cap of $49.11 billion, a price-to-earnings ratio of 33.84, a price-to-earnings-growth ratio of 1.61 and a beta of 0.49. The firm has a 50-day moving average of $238.74 and a two-hundred day moving average of $235.83. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $261.25.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were paid a $0.55 dividend. The ex-dividend date was Friday, November 15th. This represents a $2.20 annualized dividend and a yield of 0.87%. This is a boost from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.